Volume 16, Number 10—October 2010
Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
|Medication||Median serum concentration, µg/mL (IQR)||Expected serum concentration range, µg/mL|
|Rifampin daily and/or biweekly
*IQR, interquartile range.
†All patients with therapeutic drug monitoring levels obtained for ethambutol and pyrazinamide were taking weight-based daily doses of these medications.
- Page created: September 07, 2011
- Page last updated: September 07, 2011
- Page last reviewed: September 07, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)